We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Ultima Genomics Sequencer for Single-Cell RNA-Seq Evaluated

By LabMedica International staff writers
Posted on 19 Sep 2022

Single-cell RNA sequencing (scRNA-seq) enables the study and characterization of cellular states and pathways at ever-growing investigational scales, including the Human Cell Atlas, cell atlases for tumors and other diseases, and large-scale Perturb-Seq screens of millions of cells under genetic or drug perturbations. More...

Mostly natural sequencing-by-synthesis (mnSBS) is a new sequencing chemistry that relies on a low fraction of labeled nucleotides, combining the efficiency of non-terminating chemistry with the throughput and scalability of optical endpoint scanning within an open fluidics system to enable high-throughput sequencing.

Genomic Scientists at the Broad Institute (Cambridge, MA, USA) and their colleagues devised a library preparation method to run single-cell libraries generated with 10x Genomics' Chromium platform (Pleasanton, CA , USA) on the Ultima Genomics UG100 instrument (Newark, CA, USA), which produces single-end, rather than paired-end, reads. The method uses a PCR-based kit to convert the 10x libraries, which are designed to run on Illumina sequencers (Illumina, San Diego, CA, USA), for use with the Ultima sequencer.

The scientists demonstrated successful application in four scRNA-seq case studies of different technical and biological types, including 5′ and 3′ scRNA-seq, human peripheral blood mononuclear cells (PBMC) from a single individual and in multiplex, as well as Perturb-Seq. Benchmarking shows that results from mnSBS-based scRNA-seq are very similar to those using Illumina sequencing, with minor differences in results related to the position of reads relative to annotated gene boundaries, owing to single-end reads of Ultima being closer to gene ends than reads from Illumina.

Of the 166 genes with differences in expression for 3′ PBMC between the two sequencing platforms, most (130 genes, 78.3%) differed in the fraction of reads that were assigned by Cell Ranger to the gene out of all the reads mapped to that gene region. This suggests that this is related to how single- and paired-end reads map to different locations relative to the transcript. Ultima reads map closer to the 5′ and 3' end than do Illumina reads. Because Cell Ranger excludes reads that do not fully map within annotated gene boundaries, more Ultima reads are excluded from analysis as they are closer to gene ends. This difference in location can also lead to more multimapping or ambiguous reads.

Gilad Almogy, PhD, Ultima CEO and Cofounder, said, “The UG100 is a generic sequencing platform and is capable of accommodating most existing sequencing libraries, including libraries prepared for other platforms via a simple conversion process. Specifically, we've successfully tested sequencing of 10x single cell ATAC-seq and CITE-seq libraries, as well as other single-cell labeling approaches.”

Joshua Levin, PhD, a senior author of the study, said , “Given that it would be a lower cost, other issues would not be a problem that would prevent you from using Ultima, and that for some applications, such as T- and B-cell receptor sequencing, 5' approaches are required. Ultima has claimed it can deliver NGS of equivalent accuracy to Illumina at approximately USD 1 per Gb, compared to approximately USD 6 to USD 7 per Gb, list price, for Illumina's highest throughput NovaSeq instrument. You can change the scale of your screen.”

The authors concluded that the method was compatible with state-of-the-art scRNA-seq libraries independent of the sequencing technology. They expect mnSBS to be of particular utility for cost-effective large-scale scRNA-seq projects. The study was published on September 15, 2022 in the journal Nature Biotechnology.

Related Links:
Broad Institute
10x Genomics
Ultima Genomics
Illumina


Gold Member
Troponin T QC
Troponin T Quality Control
Serological Pipet Controller
PIPETBOY GENIUS
New
Respiratory Syncytial Virus Test
OSOM® RSV Test
New
Toxoplasma Gondii Test
Toxo IgG ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Microbiology

view channel
Image: The U.S. FDA-cleared IntelliSep rapid host response diagnostic represents a breakthrough in sepsis care (Photo courtesy of Cytovale)

Rapid Diagnostic Test Slashes Sepsis Mortality by 39%

Sepsis remains one of the most challenging and fatal conditions in contemporary healthcare, accounting for nearly one-third of all hospital-related deaths in the United States. In emergency departments... Read more

Industry

view channel
Image: The knowledge transfer partnership will further develop technology to rapidly diagnose serious and high-risk infectious diseases (Photo courtesy of Aston University)

Aston University and BG Research Partner to Commercialize Groundbreaking Medical Diagnostic

Technology that can rapidly diagnose high-consequence infectious diseases will take a major step forward towards commercialization, thanks to a new partnership. A Knowledge Transfer Partnership (KTP)... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.